Who are FlutiForm 250/10's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): FF, mometasone furoate and formoterol, Beclometasone/Formoterol, CHF 1535 50/6µg, Beclomethasone Dipropionate/Formoterol Fumarate, Budesonide/Formoterol SPIROMAX®.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/flutiform-250-10.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

FlutiForm 250/10 — Competitive Intelligence Brief

FlutiForm 250/10 (FlutiForm 250/10) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination. Area: Respiratory/Pulmonology.

phase 3 Inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (formoterol) Respiratory/Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

FlutiForm 250/10 (FlutiForm 250/10) — SkyePharma AG. FlutiForm combines fluticasone propionate (an inhaled corticosteroid) with formoterol (a long-acting beta-2 agonist) to reduce airway inflammation and improve bronchial smooth muscle relaxation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
FlutiForm 250/10 TARGET	FlutiForm 250/10	SkyePharma AG	phase 3	Inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination	Glucocorticoid receptor (fluticasone); beta-2 adrenergic receptor (formoterol)
FF	FF	GlaxoSmithKline	marketed	Inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination	Glucocorticoid receptor; beta-2 adrenergic receptor
mometasone furoate and formoterol	mometasone furoate and formoterol	Sanofi	marketed	Inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination	Glucocorticoid receptor (mometasone); beta-2 adrenergic receptor (formoterol)
Beclometasone/Formoterol	Beclometasone/Formoterol	Chiesi Farmaceutici S.p.A.	marketed	Inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination	Glucocorticoid receptor (beclometasone); beta-2 adrenergic receptor (formoterol)
CHF 1535 50/6µg	CHF 1535 50/6µg	Chiesi Farmaceutici S.p.A.	phase 3	Inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination	Glucocorticoid receptor (GR); Beta-2 adrenergic receptor (β2AR)
Beclomethasone Dipropionate/Formoterol Fumarate	Beclomethasone Dipropionate/Formoterol Fumarate	Alfredo Antonio Chetta	phase 3	Inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination	Glucocorticoid receptor; beta-2 adrenergic receptor
Budesonide/Formoterol SPIROMAX®	Budesonide/Formoterol SPIROMAX®	Teva Branded Pharmaceutical Products R&D, Inc.	phase 3	Inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination	Glucocorticoid receptor (budesonide); beta-2 adrenergic receptor (formoterol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination class)

Chiesi Farmaceutici S.p.A. · 6 drugs in this class
Alfredo Antonio Chetta · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
Sanofi · 1 drug in this class
SkyePharma AG · 1 drug in this class
Teva Branded Pharmaceutical Products R&D, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). FlutiForm 250/10 — Competitive Intelligence Brief. https://druglandscape.com/ci/flutiform-250-10. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab